卵巣がん、原発性腹膜がん、または卵管がんを有する参加者におけるAZD5335およびイトラコナゾールの薬物相互作用研究
卵巣癌、原発性腹膜癌、または卵管癌を有する参加者における、抗体薬物複合体AZD5335のTOP1阻害剤ペイロードAZ14170132の薬物動態に及ぼすイトラコナゾール(強力なCYP3A阻害剤)の影響を評価するための、非盲検固定順序第I相試験
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
調査の概要
詳細な説明
This is a non-randomized, open-label, fixed sequence study to be conducted at multiple study centers.
The study will consist of 2 parts:
Part A of the study will comprise of:
- Screening period
- Treatment period: The treatment period will comprise of Cycles 1, 2 and 3 where the participants will receive AZD5335 along with itraconazole
- Follow-up visit (not applicable for participants involved in Part B)
Part B of the study will comprise of:
- Treatment period: Cycle 4 and onwards
- Safety Follow-up period
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:AstraZeneca Clinical Study Information Center
- 電話番号:1-877-240-9479
- メール:information.center@astrazeneca.com
研究場所
-
-
-
Dublin、アイルランド、D07 R2WY
- 募集
- Research Site
-
-
-
-
-
Batumi、グルジア、6010
- 引きこもった
- Research Site
-
Tbilisi、グルジア、0114
- 引きこもった
- Research Site
-
Tbilisi、グルジア、112
- 引きこもった
- Research Site
-
-
-
-
-
Barcelona、スペイン、08023
- 募集
- Research Site
-
Logroño、スペイン、26006
- 募集
- Research Site
-
Madrid、スペイン、28040
- 募集
- Research Site
-
Madrid、スペイン、28050
- 募集
- Research Site
-
-
-
-
-
Lisbon、ポルトガル、1250-068
- 募集
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants with Platinum-resistant, relapsed, high- grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer and: (a) have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum; (b) must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion Criteria:
- Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Unresolved toxicities of Grade ≥ 2 (National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0) from prior therapy.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Uncontrolled intercurrent illness within 12 months prior to screening.
- Any other contraindication for receiving itraconazole according to the prescribing information and the Investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:AZD5335/AZD5335 + Itraconazole
In Part A, participants will receive AZD5335 alone as an intravenous (IV) infusion, and in combination with oral itraconazole, every 3 weeks (Q3W) from cycle 1 to cycle 3. In Part B, participants will receive AZD5335 as an IV infusion Q3W, from Day 1 of Cycle 4 until progression, unacceptable toxicity or any other specified criteria for discontinuation occurs. |
AZD5335 will be administered as IV infusion.
他の名前:
Itraconazole capsule will be administered orally. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the pharmacokinetics (PK) of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Maximum plasma drug concentration (Cmax)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the PK of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum plasma drug concentration (Cmax)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-17days of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Minimum plasma drug concentration (Cmin)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmin of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to the time of last measurable concentration (AUC0-t)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-t of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Terminal elimination (lambda_z)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
lambda_z of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Half life (t1/2)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
t1/2 of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Time to maximum observed concentration (tmax)
時間枠:Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
tmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
時間枠:Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The safety and tolerability of AZD5335 alone and in combination with itraconazole will be assessed. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Objective response rate (ORR)
時間枠:Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR), with the denominator defined as the number of participants in the response evaluable set. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Duration of response (DoR)
時間枠:Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression). |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Progression-free Survival (PFS)
時間枠:From Day 1 until until disease progression or death (up to 2 years)
|
The PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. |
From Day 1 until until disease progression or death (up to 2 years)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- D8991C00002
- EU CT (その他の識別子:2025-522731-34-00)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共有時間枠
AstraZeneca will meet or exceed data availability as per the commitment a made to the EFPIA PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有アクセス基準
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。